CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Bernard Le Foll

OPENALEX: A5067734183↗OPENALEX: A5122092590↗OPENALEX: A5122894226↗OPENALEX: A5135785253↗ORCID: 0000-0002-6406-4973↗

Affiliations

Organizations

Assistance Publique – Hôpitaux de Parisauthorship · FR British Lung Foundationauthorship · GB Canada Research Chairsauthorship · CA Centre for Addiction and Mental Healthauthorship · CA Copenhagen University Hospitalauthorship · DK Hôpital Louis-Mourierauthorship · FR Mahle (Austria)authorship · AT Mental Health Research Canadaauthorship · CA Public Health Ontarioauthorship · CA Start Treatment & Recovery Centersauthorship · US Technische Universität Dresdenauthorship · DE University of New Brunswickauthorship · CA University of Torontoauthorship · CA Waypoint Centre for Mental Health Careauthorship · CA

Public evidence

27 connected articles

Sex and Gender Influences on Problematic Cannabis Use and Cannabis Use Disorder: A Scoping Review Protocol2025 · medRxiv Cannabis Legalization Outcomes in Canada: Trading Off Increased Health Problem for Reduced Crime Burdens Is Not Good Enough.2026 · Europe PMC Concordance Between Urine Drug Screening and Self-Reported Use in the Context of a Pragmatic Randomized-Controlled Trial in People with <i>Prescription-Type</i> Opioid Use Disorder: Concordance entre le dépistage de drogues dans l'urine et l'usage autodéclaré dans le contexte d'un essai pragmatique contrôlé à répartition aléatoire chez des personnes présentant un trouble lié à l'usage d'opioïdes vendus sur ordonnance.2026 · Europe PMC Sex and gender influences on problematic cannabis use and cannabis use disorder: A scoping review protocol.2026 · Europe PMC Drug harms in Canada: A multi-criteria decision analysis.2026 · Europe PMC Neuromodulation for Cannabis Use: A Scoping Review.2024 · Europe PMC The effect of cannabis edibles on driving and blood THC.2024 · Europe PMC Motivations for Cannabis Use in Individuals with Social Anxiety Disorder (SAD).2023 · Europe PMC Circulating Endocannabinoids and N-Acylethanolamines in Individuals with Cannabis Use Disorder-Preliminary Findings.2023 · PubMed Central Open Access Impacts of recreational cannabis legalization on use and harms: A narrative review of sex/gender differences2023 · PubMed Central Open Access

Registered research

Connected studies

Evaluating the Efficacy of Cannabidiol for Reducing Cigarette Usenct06218056

Matched by exact identifiers only. Profile data: ORCID. Last retrieved 09/09/2026.

Implementation and Preliminary Evaluation of a 12-Week Cognitive Behavioural and Motivational Enhancement Group Therapy for Cannabis Use Disorder2023 · PubMed Central Open Access

Cannabis self-administration in the human laboratory: a scoping review of ad libitum studies.2023 · PubMed Central Open Access

The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics.2022 · Europe PMC

Association between <i>ABCB1</i> rs2235048 Polymorphism and THC Pharmacokinetics and Subjective Effects following Smoked Cannabis in Young Adults.2022 · PubMed Central Open Access

Monitoring the impact of cannabis use.2022 · PubMed Central Open Access

Medical Cannabis and Past-Year Cannabis Use Disorder Among Adult Recreational Users in the United States: Results From a Nationally Representative Sample.2022 · PubMed Central Open Access

Sex Differences in the Neuropsychiatric Effects and Pharmacokinetics of Cannabidiol: A Scoping Review.2022 · Europe PMC

The impact of cannabis legalization for recreational purposes on youth: A narrative review of the Canadian experience.2022 · PubMed Central Open Access

Influence of Cannabinoid Receptor 1 Genetic Variants on the Subjective Effects of Smoked Cannabis.2021 · Europe PMC

Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.2020 · PubMed Central Open Access

Cannabis Legalization and Acute Harm From High Potency Cannabis Products: A Narrative Review and Recommendations for Public Health.2020 · PubMed Central Open Access

Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders.2019 · PubMed Central Open Access

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.2018 · Europe PMC

The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.2016 · Europe PMC

Role of the endogenous cannabinoid system in nicotine addiction: novel insights.2015 · Europe PMC

Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Δ9-Tetrahydrocannabinol2015 · PubMed Central Open Access

Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking.2012 · Europe PMC

Bernard Le Foll - Medical Cannabis Research Engine